ArticleAmerican journal of preventive medicine2017
National and State-Specific Shingles Vaccination Among Adults Aged ≥60 Years.
Article in American journal of preventive medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- National Trends and Disparities in Herpes Zoster Vaccination Among US Older Adults With Diabetes, 2008-2023.Pharmacoepidemiology and drug safety · 2025Article
- The association between healthcare access and shingles vaccination among older adults in Virginia, United States.PloS one · 2025Article
- Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients.Human vaccines & immunotherapeutics · 2024Article
- Respiratory syncytial virus vaccination among US adults aged ≥60 years.Frontiers in immunology · 2024Article
- Shingles Vaccine Uptake Among Older Adults: Identifying Early, Later, and Nonadopters.AJPM focus · 2023Article
- Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.Vaccine · 2023Article
- Article
- Identifying optimal vaccination scenarios to reduce varicella zoster virus transmission and reactivation.BMC medicine · 2022Article
- Consumer Perceptions of a Shingles Infograph Intervention and Vaccination Plans in Community Pharmacy Settings.Innovations in pharmacy · 2022Article
- Incidence Rate of Herpes Zoster Ophthalmicus: A Retrospective Cohort Study from 1994 through 2018.Ophthalmology · 2020Observational
- Vaccination Coverage of the Elderly in Greece: A Cross-Sectional Nationwide Study.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2020Article
- The essential role of pharmacists facilitating vaccination in older adults: the case of Herpes Zoster.Human vaccines & immunotherapeutics · 2020Article
- A Community-Based Survey to Assess Knowledge, Attitudes, Beliefs and Practices Regarding Herpes Zoster in an Urban Setting.Infectious diseases and therapy · 2019Article
- Varicella zoster virus vaccines: an update.ImmunoTargets and therapy · 2019Article
- Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study.Journal of acquired immune deficiency syndromes (1999) · 2018Article
- Assessing and Improving Zoster Vaccine Uptake in a Homeless Population.Journal of community health · 2018Article
- Monitoring Interest in Herpes Zoster Vaccination: Analysis of Google Search Data.JMIR public health and surveillance · 2018Article
- An analysis of factors associated with influenza, pneumoccocal, Tdap, and herpes zoster vaccine uptake in the US adult population and corresponding inter-state variability.Human vaccines & immunotherapeutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionShingles (herpes zoster) causes substantial morbidity, especially among older adults. The shingles vaccine has been recommended for people aged ≥60 years since 2006. This study assessed recent shingles vaccination at national and state levels among adults aged ≥60 years.
methodsThe 2014 Behavioral Risk Factor Surveillance System data were analyzed in 2015 to assess shingles vaccination coverage among adults aged ≥60 years at national and state levels. Multivariable logistic regression and predictive marginal models identified factors independently associated with vaccination.
resultsShingles vaccination coverage among adults aged ≥60 years was 31.8% (95% CI=31.4%, 32.2%). Among states, shingles vaccination coverage ranged from 17.8% (95% CI=15.8%, 20.0%) in Mississippi to 46.6% (95% CI=44.3%, 48.8%) in Vermont, with a median of 33.3%. Coverage was <25% in four states and >40% in nine states. For all states, coverage was significantly higher among non-Hispanic whites compared with non-white races except for Oregon, with coverage differences ranging from -33.2% in the District of Columbia to 0.9% in Oregon and a median of -16.0%. Characteristics independently associated with vaccination were age, race/ethnicity, sex, education, employment status, household income, region, perceived health status, health insurance status, personal healthcare provider, routine checkup status, and whether reporting that cost was a barrier to seeing a doctor.
conclusionsCoverage varied dramatically by state. State-level comparisons may aid in designing tailored intervention programs through sharing of best practices. Strategies are needed to mitigate financial barriers for both provider and patients, improve awareness, and increase provider recommendation of the vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.